Adds ABS-1230, a clinical-stage, potential first-in-class precision therapy for KCNT1+ epilepsy
5 Revealing Analyst Questions From Jazz Pharmaceuticals’s Q2 Earnings Call
Jazz Pharmaceuticals (NASDAQ:JAZZ) Reports Bullish Q2 CY2026, Guides for Strong Full-Year Sales
– Continued commercial execution drives record total revenues of $1.2 billion (+16% YoY) –
Jazz Pharmaceuticals (JAZZ) Q2 Earnings: What To Expect
Barchart Research What to Expect from JAZZ Earnings JAZZ Generated July 31, 2026 Current Price $252.86 EPS Estimate $$5.06 Consensus Rating Strong Buy Average Move 6.51% Jazz Pharmaceuticals' Rare Oncology...
DUBLIN , July 20, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced it will report its 2026 second quarter financial results on Monday, August 3, 2026, after the close...
The S&P 500 Index ($SPX ) (SPY ) on Friday closed down -1.01%, the Dow Jones Industrial Average ($DOWI ) (DIA ) closed down -0.77%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down -1.49%. September...
The S&P 500 Index ($SPX ) (SPY ) today is down -0.87%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is down -0.12%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -1.76%. September E-mini S&P futures...